长风药业（02652）今日在港交所挂牌上市，股价表现强劲，盘中大涨218.64%。开盘报47港元，较发行价14.75港元大幅上涨32.25港元，成交额达2.71亿港元。不计手续费，每手500股账面获利16,125港元。
长风药业此次IPO备受投资者青睐。公司公开发售部分获得6697.8倍超额认购，一手（500股）中签率仅为1%。国际配售部分也录得12.74倍超额认购。公司发行4119.8万股，每股定价14.75港元，募集资金净额约5.25亿港元。
长风药业主要专注于吸入技术及吸入药物的研发、生产及商业化，尤其针对呼吸系统疾病治疗。公司已获得国家药监局及美国FDA六项产品批准，其中CF017（吸入用布地奈德混悬液）是公司首个获批产品，于2021年5月获批后迅速纳入中国集中采购计划。根据行业数据，CF017在2024年占中国布地奈德吸入药物市场约16%的份额。公司强劲的研发能力、产品管线以及在呼吸系统疾病治疗领域的领先地位，成为投资者追捧的主要原因。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.